BioTissue® Showcases Scientific Leadership at Academy Meetings in October

Extensive Research Highlights Cryopreserved Amniotic Membrane’s Role in Advancing Care for Complex Ocular Surface & Corneal Conditions 

MIAMI, October 7, 2025 – BioTissue’s global leadership in ocular surface healing will take center stage this October at two of eye care’s most influential gatherings: the American Academy of Optometry Annual Meeting in Boston and the American Academy of Ophthalmology Annual Meeting in Orlando. These key meetings provide valuable opportunities for interaction between ocular physicians and industry to share ideas, receive updates on the latest research, and learn about new products and techniques. Researchers will present a podium paper and multiple scientific posters demonstrating how Cryopreserved Amniotic Membrane (CAM) helps eye care professionals manage complex corneal and ocular surface conditions, ultimately improving patient outcomes. 

“Our scientific program reflects BioTissue’s commitment to evidence-based innovation,” said Ted Davis, CEO of BioTissue. “We are proud to collaborate with leading clinicians who continue to demonstrate the regenerative power of our CAM portfolio across a wide spectrum of challenging ocular conditions. These findings not only inform today’s practice but help define the future standard of care.” 

Advancing Keratoconus Care with CAM:
At both conferences, investigators will present Effect of Cryopreserved Amniotic Membrane after Corneal Cross-Linking in Keratoconus Patients: A Controlled, Retrospective Study (Rosetta M, Gupta R). The study examined whether Prokera® Slim improves outcomes after corneal cross-linking in patients with progressive Keratoconus. Eyes treated with Prokera Slim showed significantly better visual acuity recovery at six-months and fewer post-operative complications than those managed with a Bandage Contact Lens alone. These findings highlight Prokera Slim’s potential to enhance patient safety, accelerate visual recovery, and support long-term outcomes in challenging corneal conditions.¹ This study will be presented by Dr. Rosetta at the American Academy of Optometry Annual Meeting on Thursday, October 9ᵗʰ, 8:00 a.m.–9:00 a.m. in Room 156, and will be available for viewing as an on-demand poster at the American Academy of Ophthalmology Annual Meeting in Orlando. 

Expanding Therapeutic Options in Ocular Surface Disease:
At the American Academy of Optometry Annual Meeting, a trio of posters will showcase CAM’s versatility in addressing persistent ocular surface challenges. These posters will be featured during the Joint Scientific Program/Resident Program Poster Session on Friday October 10ᵗʰ, 1:30–3:30 p.m., in the Exhibit Hall: 

• Hydrated, Shelf-Stable Cryopreserved Amniotic Membrane for the Treatment of Recalcitrant Dry Eye and Reduced Corneal Sensitivity (Ciarmiello G) evaluated a patient with chronic dry eye and reduced corneal sensitivity. After two-days of treatment with CAM360 AmnioGraft™ (CAM360 AG) in both eyes, corneal staining, sensitivity, and visual acuity improved and were maintained for six-months, with a Collagen Shield providing greater comfort than a Bandage Contact Lens. These results demonstrate CAM360 AG’s potential to deliver rapid, lasting relief while improving comfort.²

• Treatment of Glaucoma-Induced Neurotrophic Keratopathy with Shelf-Stable and Hydrated Cryopreserved Amniotic Membrane (Hoang K) described a glaucoma patient with persistent ocular surface disease. Following three-days of CAM360 AmnioGraft™ (CAM360 AG) application, corneal staining was resolved, and the patient reported significant improvement in symptoms (vision fluctuation & irritation) seven-days post CAM360 AG application. The study highlights CAM360 AG’s ability to restore corneal health and enhance quality of life when conventional therapies fail.³

• 24-hour Treatment with Aggressive Lubrication, Cryopreserved Amniotic Membrane, and a Bandage Contact Lens for Exposure Keratopathy Secondary to Lagophthalmos (Lazar I) detailed a patient with incomplete eyelid closure whose cornea failed to respond to standard treatment. After 24-hours of CAM360 AmnioGraft™ (CAM 360 AG), combined with a Bandage Contact Lens and aggressive lubrication, the corneal epithelium fully healed, and the patient reported clear, comfortable vision five-days post CAM360 AG application. This case underscores CAM360 AGs capacity for rapid corneal repair in challenging Exposure Keratopathy.⁴

Together, these investigations illustrate CAM’s (e.g., CAM360 AG & Prokera Slim) regenerative potential across a diverse spectrum of conditions that remain difficult to treat with conventional approaches. 

Full schedules for the American Academy of Optometry (Boston, October 8ᵗʰ – 11ᵗʰ, 2025) and the American Academy of Ophthalmology (Orlando, October 18ᵗʰ – 20ᵗʰ, 2025) meetings are available at www.aaopt.org/meetings/academy-2025-boston and www.aao.org/annual-meeting. 

References: (American Academy of Optometry Meeting 2025) 

1. Rosetta, M. Effects of Cryopreserved Amniotic Membrane after Corneal Cross-Linking in Keratoconus Patients: A Controlled, Retrospective Study, Abstract Presentation, 2025 American Academy of Optometry Meeting. 
2. Ciarmiello, Hydrated, Shelf-Stable Cryopreserved Amniotic Membrane for the Treatment of Recalcitrant Dry Eye and Reduced Corneal Sensitivity. Poster Presentation, 2025 American Academy of Optometry Meeting.
3. Hoang, Saving Glaucoma Corneas One Cryopreserved Amniotic Membrane At A Time. Poster Presentation, 2025 American Academy of Optometry Meeting.
4. Lazar, I. 24-Hour Treatment with Aggressive Lubrication, Cryopreserved Amniotic Membrane, and a Bandage Contact Lens for Exposure Keratopathy Secondary to Lagophthalmos, Poster Presentation, 2025 American Academy of Optometry Meeting.

References: (American Academy of Ophthalmology Meeting 2025) 

1. Gupta, R. Effects of Cryopreserved Amniotic Membrane after Corneal Cross-Linking in Keratoconus Patients: A Controlled, Retrospective Study, Abstract Presentation, 2025 American Academy of Ophthalmology Meeting.

# # # 

About BioTissue, Inc. 

BioTissue® is an emerging biotechnology company and leader in harnessing the unique power of human birth tissue to support regenerative healing across a wide variety of conditions throughout the body, specializing in ocular surface disease, neurotrophic keratitis, and non-healing corneal defects. BioTissue’s portfolio of cryopreserved amniotic membrane products use its proprietary CryoTek® cryopreservation technology, designed to retain the tissue’s structural and functional integrity. The company continues to break new ground with multiple Investigational New Drug (IND) clinical trials as the company pursues Biologic License Applications (BLAs) for products to treat patients’ unmet clinical needs. BioTissue is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed over1 million human implants with its products and published 420 peer-reviewed publications supporting BioTissue’s platform technology. Learn more at biotissue.com.    

Media Contact 

Laura DiCaprio, APR 

McDougall Communications for BioTissue 

[email protected] or (585) 434-2153